HCL-TECHNOLOGIES
Three winners of HCL Grant 2017 across categories of Environment, Health and Education were today announced at a ceremony held at HCL Technologies Hub, Noida. Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs , presided over the ceremony as the Chief Guest and felicitated the winners. Each winning NGO receives a Grant of up to INR 5 crores.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170221006559/en/
At the occasion, Shri Arun Jaitley also released a compendium titled “The Fifth Estate - NGOs transforming Rural India in Environment, Health and Education ,” which is a compilation of all the finalists of the second edition of HCL Grant.
Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs, congratulated the winners of HCL Grant 2017 and appreciated the work of HCL and the jury.
Addressing the gathering he said , “I must compliment HCL for going into the larger society, creating an independent jury, looking at areas which need support and getting the jury to select the best so that the winners can be role models for others.”
Malcolm Gladwell , an eminent author and speaker, attended the ceremony as a Special Guest and addressed the gathering comprising Board members, senior leadership and other distinguished guests from various walks of life.
The winning NGOs across three categories are:
- Environment - Foundation of Ecological Security (Gujarat)
- Health - Child in Need Institute (CINI) (West Bengal)
- Education - MelJol (Maharashtra)
Ms. Robin Abrams, Chairperson of Jury, HCL Grant, said, “HCL Grant is so much more than the fund itself. The mark of the strategic value of any grant is leverage. From the focus on governance and sustainability, sharing of best practices and how corporates and their employees can engage with NGOs – HCL Grant delivers on strategic value for the NGOs of India and for India’s Fifth Estate. It is exciting to be a part of this kind of leverage.”
HCL Grant, a CSR commitment by HCL through HCL Foundation, envisions to contribute to rural development by strengthening NGOs through deep institutional involvement and commitment. The Grant stands testimony to the fact that only strong governance structures management capabilities and reliable impact measurement systems within NGOs can help them take up and sustain high impact, complex and social transformational projects.
The winning NGOs have been selected by an eminent jury panel. Members of the panel are Ms. Robin Abrams – Former President of Palm Computing, and the longest serving Board member of HCL Technologies; Dr. Isher Judge Ahluwalia - Leading Economist and Chairperson, Board of Governors, the Indian Council for Research on International Economic Relations; Ms. Pallavi Shroff - Eminent Legal Counsel, Shardul Amarchand Mangaldas & Co.; Mr. B.S. Baswan - Former Director, Indian Institute of Public Administration; Mr. Richard Lariviere - President, Field Museum, Chicago and Former President of the University of Oregon; Dr. John E. Kelly – Senior Vice President, Cognitive Solutions and Research, IBM Corporation; and Mr. Shiv Nadar – Founder & Chairman, HCL and Shiv Nadar Foundation.
For more information please visit www.hcltech.com/HCL-Grant .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170221006559/en/
Contact:
HCL Technologies
Ajay Davessar, +91 120 43828280
VP & Global
Head - Corporate Communications
Ajay.davessar@hcl.com
Link:
Social Media:
https://www.facebook.com/https://www.facebook.com/HCLTechnologies
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom